MedTrace Logo

Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure

NCT02057900 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-07-10

No results posted yet for this study

Summary

The purpose of the study is to assess the feasibility and safety of a transplantation of cardiac-committed progenitor cells derived from human embryonic stem cells in patients with severe heart failure.

Conditions

  • Ischemic Heart Disease

Interventions

BIOLOGICAL

Human embryonic stem cell-derived CD15+ Isl-1+ progenitors

Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Philippe Menasché, MD, PhD · Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, Paris, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-27
Primary Completion
2018-03-22
Completion
2018-03-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02057900 on ClinicalTrials.gov